SECO
SECO
March 06, 2015
3 min watch
Save

VIDEO: Drop to treat presbyopia in phase 2 trials

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ATLANTA – Liquid Vision from Presbyopia Therapies is being investigated in phase 2 clinical trials as a topical, reversible, short-term treatment for presbyopia, reported Terry Kim, MD, here at SECO

Different from pilocarpine, the drop acts only on the sphincter muscle, not the ciliary muscle, thereby creating miosis without accommodative effect. 

Some patients have shown improvement of up to six lines of near vision, with good distance vision, he said.